Gene regulation of brain natriuretic peptide in cardiocyte hypertrophy by α1-adrenergic stimulation

O. Nakagawa, Hiroshi Itoh, M. Harada, Y. Komatsu, T. Yoshimasa, K. Nakao

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

1. We previously demonstrated that brain natriuretic peptide (BNP) is a cardiac hormone mainly produced in the ventricle, while the major production site of atrial natriuretic peptide (ANP) is the atrium. The production and secretion of BNP and ANP in the hypertrophied ventricles were markedly augmented, serving as a compensation mechanism against ventricular overload by their natriuretic, diuretic and vasodilatory actions. 2. In the present study, we prepared an in vitro model of cardiocyte hypertrophy using cultured neonatal rat ventricular cardiocytes and α1-adrenergic stimulation, and examined the gene expressions of BNP and ANP during the process of cardiocyte hypertrophy. 3. The treatment of cultured ventricular cardiocytes with phenylephrine evoked cardiocyte hypertrophy around 24h after the treatment, which was characterized by augmented expression of the myosin light chain-2 gene and increase in cell size. 4. In this model of cardiocyte hypertrophy, the steady-state level of BNP mRNA rapidly increased to the maximal level within 1h after the treatment. In contrast, ANP mRNA began to increase at 3h, and accumulated during the course of cardiocyte hypertrophy. The secretion of BNP from ventricular cardiocytes was also stimulated more rapidly than the ANP secretion. 5. These results indicate that the gene expression of BNP is distinctly regulated from that of ANP in cardiocyte hypertrophy, and suggest a discrete pathophysiological role of BNP as an 'emergency' cardiac hormone against ventricular overload.

Original languageEnglish
JournalClinical and Experimental Pharmacology and Physiology
Volume22
Issue numberSUPPL. 1
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Brain Natriuretic Peptide
Adrenergic Agents
Hypertrophy
Atrial Natriuretic Factor
Genes
Hormones
Gene Expression
Messenger RNA
Phenylephrine
Cell Size
Diuretics
Emergencies

Keywords

  • α-adrenergic receptor
  • Atrial natriuretic peptide
  • Brain natriuretic peptide
  • Cardiac hypertrophy
  • Gene expression
  • Ventricular cardiocytes

ASJC Scopus subject areas

  • Physiology
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Gene regulation of brain natriuretic peptide in cardiocyte hypertrophy by α1-adrenergic stimulation. / Nakagawa, O.; Itoh, Hiroshi; Harada, M.; Komatsu, Y.; Yoshimasa, T.; Nakao, K.

In: Clinical and Experimental Pharmacology and Physiology, Vol. 22, No. SUPPL. 1, 1995.

Research output: Contribution to journalArticle

@article{0ab027e3002140dfb77b1a67088b2c2f,
title = "Gene regulation of brain natriuretic peptide in cardiocyte hypertrophy by α1-adrenergic stimulation",
abstract = "1. We previously demonstrated that brain natriuretic peptide (BNP) is a cardiac hormone mainly produced in the ventricle, while the major production site of atrial natriuretic peptide (ANP) is the atrium. The production and secretion of BNP and ANP in the hypertrophied ventricles were markedly augmented, serving as a compensation mechanism against ventricular overload by their natriuretic, diuretic and vasodilatory actions. 2. In the present study, we prepared an in vitro model of cardiocyte hypertrophy using cultured neonatal rat ventricular cardiocytes and α1-adrenergic stimulation, and examined the gene expressions of BNP and ANP during the process of cardiocyte hypertrophy. 3. The treatment of cultured ventricular cardiocytes with phenylephrine evoked cardiocyte hypertrophy around 24h after the treatment, which was characterized by augmented expression of the myosin light chain-2 gene and increase in cell size. 4. In this model of cardiocyte hypertrophy, the steady-state level of BNP mRNA rapidly increased to the maximal level within 1h after the treatment. In contrast, ANP mRNA began to increase at 3h, and accumulated during the course of cardiocyte hypertrophy. The secretion of BNP from ventricular cardiocytes was also stimulated more rapidly than the ANP secretion. 5. These results indicate that the gene expression of BNP is distinctly regulated from that of ANP in cardiocyte hypertrophy, and suggest a discrete pathophysiological role of BNP as an 'emergency' cardiac hormone against ventricular overload.",
keywords = "α-adrenergic receptor, Atrial natriuretic peptide, Brain natriuretic peptide, Cardiac hypertrophy, Gene expression, Ventricular cardiocytes",
author = "O. Nakagawa and Hiroshi Itoh and M. Harada and Y. Komatsu and T. Yoshimasa and K. Nakao",
year = "1995",
language = "English",
volume = "22",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Gene regulation of brain natriuretic peptide in cardiocyte hypertrophy by α1-adrenergic stimulation

AU - Nakagawa, O.

AU - Itoh, Hiroshi

AU - Harada, M.

AU - Komatsu, Y.

AU - Yoshimasa, T.

AU - Nakao, K.

PY - 1995

Y1 - 1995

N2 - 1. We previously demonstrated that brain natriuretic peptide (BNP) is a cardiac hormone mainly produced in the ventricle, while the major production site of atrial natriuretic peptide (ANP) is the atrium. The production and secretion of BNP and ANP in the hypertrophied ventricles were markedly augmented, serving as a compensation mechanism against ventricular overload by their natriuretic, diuretic and vasodilatory actions. 2. In the present study, we prepared an in vitro model of cardiocyte hypertrophy using cultured neonatal rat ventricular cardiocytes and α1-adrenergic stimulation, and examined the gene expressions of BNP and ANP during the process of cardiocyte hypertrophy. 3. The treatment of cultured ventricular cardiocytes with phenylephrine evoked cardiocyte hypertrophy around 24h after the treatment, which was characterized by augmented expression of the myosin light chain-2 gene and increase in cell size. 4. In this model of cardiocyte hypertrophy, the steady-state level of BNP mRNA rapidly increased to the maximal level within 1h after the treatment. In contrast, ANP mRNA began to increase at 3h, and accumulated during the course of cardiocyte hypertrophy. The secretion of BNP from ventricular cardiocytes was also stimulated more rapidly than the ANP secretion. 5. These results indicate that the gene expression of BNP is distinctly regulated from that of ANP in cardiocyte hypertrophy, and suggest a discrete pathophysiological role of BNP as an 'emergency' cardiac hormone against ventricular overload.

AB - 1. We previously demonstrated that brain natriuretic peptide (BNP) is a cardiac hormone mainly produced in the ventricle, while the major production site of atrial natriuretic peptide (ANP) is the atrium. The production and secretion of BNP and ANP in the hypertrophied ventricles were markedly augmented, serving as a compensation mechanism against ventricular overload by their natriuretic, diuretic and vasodilatory actions. 2. In the present study, we prepared an in vitro model of cardiocyte hypertrophy using cultured neonatal rat ventricular cardiocytes and α1-adrenergic stimulation, and examined the gene expressions of BNP and ANP during the process of cardiocyte hypertrophy. 3. The treatment of cultured ventricular cardiocytes with phenylephrine evoked cardiocyte hypertrophy around 24h after the treatment, which was characterized by augmented expression of the myosin light chain-2 gene and increase in cell size. 4. In this model of cardiocyte hypertrophy, the steady-state level of BNP mRNA rapidly increased to the maximal level within 1h after the treatment. In contrast, ANP mRNA began to increase at 3h, and accumulated during the course of cardiocyte hypertrophy. The secretion of BNP from ventricular cardiocytes was also stimulated more rapidly than the ANP secretion. 5. These results indicate that the gene expression of BNP is distinctly regulated from that of ANP in cardiocyte hypertrophy, and suggest a discrete pathophysiological role of BNP as an 'emergency' cardiac hormone against ventricular overload.

KW - α-adrenergic receptor

KW - Atrial natriuretic peptide

KW - Brain natriuretic peptide

KW - Cardiac hypertrophy

KW - Gene expression

KW - Ventricular cardiocytes

UR - http://www.scopus.com/inward/record.url?scp=0029558515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029558515&partnerID=8YFLogxK

M3 - Article

VL - 22

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - SUPPL. 1

ER -